Dynavax Technologies Corporation (NASDAQ:DVAX) went down by -9.37% from its latest closing price compared to the recent 1-year high of $21.39. The company’s stock price has collected -20.24% of loss in the last five trading sessions. Barron’s reported on 09/13/21 that The U.K. Canceled a Vaccine Deal. Here’s the Fallout for Stocks.
Is It Worth Investing in Dynavax Technologies Corporation (NASDAQ :DVAX) Right Now?
Dynavax Technologies Corporation (NASDAQ:DVAX) scored a price-to-earnings ratio above its average ratio, recording 24.19 x from its present earnings ratio. Plus, the 36-month beta value for DVAX is at 1.44. Opinions of the stock are interesting as 5 analysts out of 5 who provided ratings for Dynavax Technologies Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $26.25, which is $18.8 above the current price. DVAX currently public float of 111.24M and currently shorts hold a 15.85% ratio of that float. Today, the average trading volume of DVAX was 1.71M shares.
DVAX’s Market Performance
DVAX stocks went down by -20.24% for the week, with a monthly drop of -27.25% and a quarterly performance of -43.04%, while its annual performance rate touched 2.76%. The volatility ratio for the week stands at 10.96% while the volatility levels for the past 30 days are set at 7.11% for Dynavax Technologies Corporation. The simple moving average for the period of the last 20 days is -21.54% for DVAX stocks with a simple moving average of -46.03% for the last 200 days.
Analysts’ Opinion of DVAX
Many brokerage firms have already submitted their reports for DVAX stocks, with Goldman repeating the rating for DVAX by listing it as a “Buy.” The predicted price for DVAX in the upcoming period, according to Goldman is $38 based on the research report published on January 06th of the current year 2022.
Goldman, on the other hand, stated in their research note that they expect to see DVAX reach a price target of $19. The rating they have provided for DVAX stocks is “Buy” according to the report published on August 06th, 2021.
H.C. Wainwright gave a rating of “Buy” to DVAX, setting the target price at $12 in the report published on August 07th of the previous year.
DVAX Trading at -28.12% from the 50-Day Moving Average
After a stumble in the market that brought DVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.17% of loss for the given period.
Volatility was left at 7.11%, however, over the last 30 days, the volatility rate increased by 10.96%, as shares sank -26.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.98% lower at present.
During the last 5 trading sessions, DVAX fell by -20.24%, which changed the moving average for the period of 200-days by -19.02% in comparison to the 20-day moving average, which settled at $9.36. In addition, Dynavax Technologies Corporation saw -47.05% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at DVAX starting from Novack David F, who sale 41,862 shares at the price of $10.57 back on Mar 03. After this action, Novack David F now owns 73,213 shares of Dynavax Technologies Corporation, valued at $442,481 using the latest closing price.
Spencer Ryan, the CEO and Director of Dynavax Technologies Corporation, sale 83,108 shares at $10.56 during a trade that took place back on Mar 03, which means that Spencer Ryan is holding 129,771 shares at $877,923 based on the most recent closing price.
Stock Fundamentals for DVAX
Current profitability levels for the company are sitting at:
- +30.43 for the present operating margin
- +60.28 for the gross margin
The net margin for Dynavax Technologies Corporation stands at +16.51.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.75.